The iron-regulated proteins (IRPs) of five group B meningococcal strains expressing class 2 outer membrane proteins were compared with those of five strains expressing class 3 proteins. Three to four high-molecularweight IRPs were expressed by each strain, but their molecular sizes varied between strains and were not related to class 2 or 3 protein expression. Transferrin and hemoglobin could be used as a sole iron source. By using anti-human transferrin antibodies, it was shown that meningococcal cells and purified outer membranes bound transferrin. Growth under conditions of iron limitation caused a several-fold increase in the amount of transferrin bound to the cell surface. The transferrin-binding protein was detergent solubilized from outer membranes and partially purified. The isolated protein bound human transferrin and had an apparent molecular mass of 70 kilodaltons. To evaluate the potential of vaccines containing IRPs, we prepared outer membrane vaccines from strains M986-NCV-1 (M986) (-:2a:Pl.2) and 44/76-M25 (44/76) (-:15:P1.15) grown to fully express their IRPs. Both vaccines induced significant anti-IRP antibodies as measured by enzyme immunoassay and by Western immunoblot with both M986 and 44/76 outer membranes. By Western blot analysis, the M986 vaccine induced antibodies to two different IRPs, one of which was shared with 44/76. Since the IRPs are major in vivo-expressed outer membrane proteins and are required for survival in vivo, these proteins should be evaluated for their usefulness in a group B meningococcal vaccine.
Invasive human pathogens must acquire iron for growth from host iron-binding proteins. In the mammalian host, there is essentially no soluble iron, because the iron is complexed with different iron-binding proteins, such as hemoglobin, transferrin, and lactoferrin. The latter two proteins have very high binding affinities for iron. Nonpathogenic or noninvasive bacteria do not have the ability to acquire the needed organic iron (14) . There is now considerable evidence suggesting that the ability of a variety of human pathogens to produce disease is directly related to their ability to obtain iron (24) . Pathogens have evolved a number of mechanisms for acquiring iron from the host. Some, like Escherichia coli and Salmonella spp., produce soluble factors called siderophores to chelate iron from the medium or host (12, 14) . Others, like the pathogenic neisseriae, are able to acquire iron from the host by other mechanisms. The neisseriae elaborate a number of new proteins on their cell surface when grown under conditions of iron limitation (4, 25) . These proteins are referred to as ironregulated proteins (IRPs) .
The neisserial IRPs range in molecular mass from 36 to over 100 kilodaltons (kDa) (2, 13) . The role these proteins play in the organism's ability to survive in the host has not been determined. Simonson et al. (19) found that a 36.5-kDa protein firmly bound radioactive iron. This protein may be involved in iron transport. It is known that neisseriae can acquire iron from human transferrmn and lactoferrin but are unable to acquire iron from bovine transferrin and lactoferrin (15) or the closely related chicken protein conalbumin (9). In addition, neisseriae cannot take up the transferrin-bound iron unless they are in direct contact with the protein (1) . These data suggest that neisseriae have a specific transferrin-* Corresponding author.
binding protein. Iron-starved meningococci express a cell surface receptor(s) for acquisition of iron from transferrin (19) . The receptor was specific for transferrin and was saturable. Dyer et al. (4) isolated a mutant of meningococcal strain M986-NCV-1 (M986) that lacked a 70-kDa iron-regulated outer membrane protein that was unable to take up iron from either transferrin or lactoferrin. However, they later isolated revertants still lacking the 70-kDa protein but able to bind transferrin normally (25) . Schryvers and Morris (18) described a 71-kDa meningococcal transferrin receptor protein; however, additional studies with affinity purification of chemically modified transferrin suggested that the receptor may be a complex of two proteins, including a 98-kDa protein (16, 17) .
The present studies were initiated to study the outer membrane protein composition of Neisseria meningitidis grown under different simulated in vivo conditions so as to identify proteins that may not be seen in cells grown under the usual laboratory conditions. Ideally, an outer membrane protein vaccine should contain those proteins that are expressed during disease. We present data on the outer membrane proteins induced as a result of growth under various iron-limited conditions. Outer membrane protein vaccines were prepared from two meningococcal strains grown to express IRPs. MATERIALS The antibodies were'visualized by using horseradish peroxidase-anti-immunoglobulin conjugates, followed by the substrate 4-chloro-1-naphthol (21 The completed dot-blots and immunoblots were scanned with a laser densitometer (Pharmacia LKB, Piscataway, N.J.), and the data were integrated to quantitate the amount of transferrin bound.
Iodination of human transferrin. Transferrin was labeled with 1251I by using lodobeads (Pierce Chemical Co., Rockford, Ill.). A 1-mg/ml solution of transferrin was prepared in 40 mM Tris hydrochloride (Tris-HCI)-20 mM sodium bicarbonate (pH 7.5), and 500 jig was added to the lodobeads containing 500 jiCi of 1251I solution. After 15 min of incubation, the reaction mixture was transferred to a Sephadex G-25 column to separate labeled protein from free iodide. Fractionation of outer membrane proteins by gel filtration. An OMV preparation from strain M986-NCV-1, grown to express the IRPs, was solubilized for 2 h at 4°C in 0.1 M Tris-HCI buffer, pH 7.0, containing 1% Sarkosyl (Sigma). Insoluble material was removed by centrifugation for 2 h at 100,000 x g. The supernatant, shown by dot-immunoblot to contain most of the transferrin-binding activity, was applied to a column (1.5 by 100 cm) containing Sephacryl S-300 (Pharmacia LKB). The elution buffer was the same as the solubilization buffer. Four volumes of 95% ethanol were added to each fraction to recover protein. The precipitates were dissolved in water. Each fraction was examined by SDS-PAGE and by a dot-blot transferrin-binding assay. Fractions shown to contain transferrin-binding activity by dot-blot were incubated for 20 min at 37°C in SDS-PAGE sample buffer and then separated by SDS-PAGE and electroblotted onto nitrocellulose. The nitrocellulose was blocked with 3% gelatin in Tris-buffered saline with Tween 20 and then incubated with '25I-labeled transferrin for 5 h.
After several washes in Tris-buffered saline with Tween 20, the nitrocellulose was exposed to X-ray film for autoradiography.
Vaccine preparation and immunization of mice. Outer membrane protein vaccines were prepared from the nonencapsulated variants M986-NCV-1 (M986) (-:2a:P1.2) and 44/76-M25 (44/76) (-:15:P1.16). The M986 variant was selected as a naturally occurring capsuleless mutant by using group B meningococcal antiserum agar. The 44/76 variant was selected on antiserum agar following ethyl methanesulfonate mutagenesis.
Vaccines were prepared from the type 2 and type 15 strains grown with induced IRPs. The OMV were prepared from the cells as described above and then extracted with 2% (wt/vol) sodium deoxycholate (Sigma) in 30 mM Tris-HCI-2 mM EDTA (pH 8.5) at room temperature for 30 min. The LPS-depleted vesicles were pelleted by centrifugation at 150,000 x g and washed twice with water to remove the detergent. The protein content of the treated vesicles was measured by the method of Lowry et al. (8) , and the LPS content was measured by an SDS-PAGE method (21) .
LPS-depleted OMV were mixed in a ratio of 1:100 with aluminum hydroxide. The protein was also prepared in phosphate-buffered saline without adjuvant. Groups of 10 4-to 6-week-old female NIH general purpose mice were immunized with a single 5-jig intraperitoneal dose of the vaccine.
Mice were bled 3 weeks later.
Mouse sera were examined for anti-outer membrane antibodies by enzyme-linked immunosorbent assay (ELISA) (6) with OMV purified from the vaccine strains grown with sufficient iron or under iron-limited conditions. The OMV were coated onto the polystyrene plates at 4 jig of protein per ml. The A405 was measured after 20 to 50 min and extrapolated to 100 min. The were also examined for bactericidal antibodies by using baby rabbit sera as the source of complement (5) . RESULTS Induction of IRPs. Removal of free ferric ions from the growth medium caused the appearance, as expected, of new proteins of between 70 and 108 kDa in the outer membrane of meningococcal strain M986-NCV-1 (Fig. 1) . Cells grown in the complete Catlin medium showed three high-molecularmass bands above 70 kDa. Addition of 50 ,iM Desferal resulted in expression of four new high-molecular-mass proteins. The two prominent high-molecular-mass proteins seen in the medium with sufficient iron appeared to be downregulated.
IRPs could be induced by growing M986-NCV-1 in Catlin medium containing 30% iron-saturated human transferrin (Fig. 2A, lane 3) . Examining the doublet protein bands at about 85 kDa, it is evident that the upper band was not induced as occurred with Desferal. Essentially the same results were seen when the strain was grown with hemoglobin as the only source of iron (Fig. 2A, lane 4) . Only partial induction of IRPs occurred when 20% fetal calf serum was added to Catlin medium without added iron (Fig. 2B, lane 4) .
To simulate in vivo conditions, strain M986-NCV-1 was grown in stationary culture in RPMI-1640 containing 20% fetal calf serum, and under these conditions IRPs were expressed (Fig. 2B, lane 5 ). An additional 51-kDa protein was induced in the tissue culture medium independent of iron levels when the organisms were grown in stationary cultures and when grown under low pH and is probably a stress protein (data not shown). Additional higher antibody binding to membranes containing the IRPs. The adjuvant had little effect (data not shown).
The specificity of the antibodies was evaluated by immunoblotting (Fig. 6) . The sera were reacted against SDS-PAGE-separated M986 and 44/76 outer membranes prepared from cells grown under iron-sufficient and iron-limited conditions. It can be seen that three IRPs in M986 were To obtain a preliminary indication of whether the antibodies to the IRPs detected by immunoblotting were also bactericidal, the mouse sera prepared to the M986 vaccine were examined for the ability to kill M986 grown with sufficient iron or under iron-deficient conditions (Fig. 7) . The bactericidal activity of the sera was shifted to higher titers against the organisms expressing IRPs. Similar experiments were done with strain 44/76 and the -15:P.16 vaccine serum, but 44/76 was killed at bactericidal titers in excess of 1:640 by many of the sera with or without the IRPs expressed.
DISCUSSION
Induction of new proteins under conditions of iron limitation is a well-known phenomenon in different microorganisms (12) . The meningococcus is obligately dependent on iron for growth and can obtain the iron from a number of sources. In its normal environment, most of the iron is complexed with protein. Therefore, a set of IRPs are induced under conditions of very low free iron (2, 13 (Fig. 4 ).
An effective vaccine against group B meningococcal disease will need to contain outer membrane proteins, because the group B polysaccharide, in contrast to the other meningococcal polysaccharides, does not stimulate protective antibodies. However, outer membrane protein vaccines are in general too serotype specific and do not contain those outer membrane proteins normally expressed only under in vivo conditions. The outer membrane IRPs are critical cell surface proteins, and it is possible that antibodies against these proteins either are bactericidal or will block invasion. Expression of the IRPs can be induced without cell division. Meningococci grown with relatively low iron levels and then transferred to fresh medium containing 50 ,uM Desferal did not divide but expressed the IRPs, including the 105-kDa lactoferrin-binding protein (17) , shown in Fig. 1 as the 108-kDa band. This allowed us to obtain sufficient cell yields to prepare serotype 2 and serotype 15 outer membrane protein vaccines containing expressed IRPs.
There was little cross-reactivity in the mice between the serotypes 2 and 15, unless the IRPs were also present. The immunogenicity of the IRPs in mice was confirmed by Western blot analysis. An important finding was that the major 74-kDa IRP appeared to be antigenically the same in the two quite divergent serotypes.
The vaccines were administered with and without adsorption to aluminum hydroxide. In contrast to our previous vaccines, the present vaccines did not contain capsular polysaccharide. The aluminum hydroxide had no demonstrable effect on the antibody response to the outer membrane proteins, in marked contrast to earlier studies in mice with vaccines containing aluminum hydroxide and polysaccharide and lipopolysaccharide-depleted outer membranes (6, 22) .
There is good evidence that the IRPs are expressed in vivo and that they induce detectable antibody levels as a consequence of infection in children (2) . These proteins are critical to the survival of the organisms in vivo, are immunogenic, and become major outer membrane proteins with iron limitation. Meningococcal outer membrane protein vaccines should therefore contain these proteins.
